Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 April 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Prediction of primary nonresponse to infliximab therapy

January's publication of the Alimentary Pharmacology & Therapeutics investigates early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.

News image

Primary nonresponse, defined as lack of clinical benefit during the induction phase, occurs in up to 30% of IBD patients treated with infliximab.

The mechanisms underlying primary nonresponse have not yet been clearly defined.

Dr Bar-Yoseph and colleagues evaluated the association of early induction infliximab and anti-infliximab antibody levels with primary nonresponse.

A retrospective observational case-control study of inflammatory bowel disease patients treated with infliximab and followed at Sheba Medical Center between 2009 and 2016 was performed.

The team measured pre-infusion infliximab and antibodies to infliximab (ATI) by previously described drug-tolerant ELISA assay.

Antibodies to infliximab appeared more frequently in nonresponders
Alimentary Pharmacology & Therapeutics

The researchers identified 35 primary nonresponders and matched with 105 primary responders.

Both week 2 and week 6 infliximab levels were significantly lower among primary nonresponders compared to responders.

The team observed that antibodies to infliximab appeared more frequently, and at higher levels in nonresponders compared to responders.

Moreover, week 2 infliximab levels <6.8 μg/mL, and antibodies to infliximab levels >4.3 μg/mL-eq were predictive of primary nonresponse.

The researchers found that among the other clinical and demographic variables, higher baseline ulcerative colitis clinical score, infliximab monotherapy, prior adalimumab therapy and previous Crohn's disease-related surgeries were also associated with an increased risk of primary nonresponse.

Dr Bar-Yoseph's team concludes, "Infliximab levels below 6.8 μg/mL and antibodies to infliximab levels above 4.3 μg/mL-eq before the second infusion are associated with primary nonresponse, especially among Crohn's disease patients."

Aliment Pharmacol Ther 2018: 47(2): 212–218
05 January 2018

Go to top of page Email this page Email this page to a colleague

 24 April 2018 
It is unknown if primary sclerosing cholangitis is a rare disease in patients of black race, or reflects selection bias of sampled cohorts

 24 April 2018 
PPI and risk of stroke
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 20 April 2018 
Obesity and physical activity in diverticulosis
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 20 April 2018 
Worldwide H.pylori prevalence
 19 April 2018 
Fibrosis in patients with chronic hepatitis B
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA
 18 April 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 18 April 2018 
Hep C treatment for sustained virologic response
 18 April 2018 
Endoscopic necrosectomy reduces risk of death 
 17 April 2018 
Colorectal cancer screening and ethnic inequities
 17 April 2018 
Training programs should consider radiation education for advanced endoscopy fellows
 17 April 2018 
Aspirin and pancreatic cancer
 16 April 2018 
Surgery for colorectal polyps has increased 
 16 April 2018 
Advanced fibrosis can be ruled out in primary health care patients
 16 April 2018 
Antibiotic use and colorectal adenoma
 13 April 2018 
Colorectal cancer cell lines
 13 April 2018 
Teduglutide for children with short bowel syndrome
 13 April 2018 
Infliximab and corticosteroid-free clinical remission in Crohn's
 12 April 2018 
Prescriptions for opiate drugs amongst primary care patients with IBD
 12 April 2018 
non–Clostridium difficile bacterial infections in IBD
 12 April 2018 
Lower GI bleeding related to comorbidity
 11 April 2018 
Bile acid deficiency in IBS 
 11 April 2018 
Stem cell therapy for fistulas in Crohn's
 11 April 2018 
Physician perception of IBD trial results
 10 April 2018 
Overweight in childhood and type 2 diabetes
 10 April 2018 
immunoglobulin G associates with clinical features of IBD
 10 April 2018 
T-cells repertoires in celiac disease
 09 April 2018 
Biomarker tests for colorectal cancer screening
 09 April 2018 
Fecal transplantation in C. difficile infection and treatment outcome 
 09 April 2018 
No weigh-loss drug improved all cardiometabolic risk factors
 06 April 2018 
Colonoscopy and colorectal cancer mortality
 06 April 2018 
Eosinophilic esophagitis and health-related quality of life
 05 April 2018 
Random biopsies for neoplasia in IBD
 05 April 2018 
Laparoscopic Nissen fundoplication for GERD treatment
 04 April 2018 
Alpha‐1 antitrypsin deficiency and liver disease
 04 April 2018 
Adjuvant chemotherapy for advanced colon cancer
 29 March 2018 
Prevention of metachronous gastric cancer
 29 March 2018 
Acute lower GI bleeding
 28 March 2018 
Decision aid used by IBD patients
 28 March 2018 
Transition for young adults with IBD
 28 March 2018 
Amitriptyline in functional dyspepsia
 27 March 2018 
Emergency department utilization for IBD 
 27 March 2018 
Management of hemorrhoids in the USA
 27 March 2018 
Adult ulcerative colitis
 26 March 2018 
Biological therapy response in IBD 
 26 March 2018 
Obesity and diverticulosis
 26 March 2018 
Practice guidelines for chronic constipation
 23 March 2018 
Health-related quality of life in eosinophilic esophagitis
 23 March 2018 
Genetics and chronic liver disease
 23 March 2018 
Global prevalence of H.pylori
 22 March 2018 
H. pyloris and gastric cancer
 22 March 2018 
Pancreatitis after IBS treatment 

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us